Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Next Previous
X
Search
Drug Profile

Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Alternative Names: Alprolix; BIIB-029; Coagulation factor IX recombinant immunoglubulin G1 fusion protein; Eftrenonacog alfa; Factor IX-Fc; FIX-Fc; Recombinant factor IX Fc; rFIXFc

Latest Information Update: 12 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Biogen; Bioverativ; Swedish Orphan Biovitrum
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 31 Dec 2023 Launched for Haemophilia B in Iraq, Israel and Turkey (IV) prior to December 2023
  • 05 Dec 2020 Efficacy and adverse events data from a phase III PUPs B-LONG trial in Haemophilia B presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
  • 13 Jul 2020 Safety and efficacy data from the phase III PUPs B-LONG trial in Haemophilia B released by Sobi and Sanofi

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top